We are live on
!
Find out more
FLAM
First Light Asset Management Portfolio holdings
AUM
$1.65B
1-Year Est. Return
203.21%
This Fund
S&P 500
This Quarter
Est. Return
+26.21%
1 Year Est. Return
+203.21%
3 Year Est. Return
+364.25%
5 Year Est. Return
+595.91%
10 Year Est. Return
+10,683%
AUM
$770M
AUM Growth
+$142M
(+23%)
Cap. Flow
+$8.71M
Cap. Flow
% of AUM
1.13%
Top 10 Holdings %
Top 10 Hldgs %
48.86%
Holding
67
New
8
Increased
35
Reduced
18
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AERI
Aerie Pharmaceuticals
AERI
|
+$20.9M |
| 2 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$20.3M |
| 3 |
DVAX
Dynavax Technologies
DVAX
|
+$13.3M |
| 4 |
Halozyme
HALO
|
+$8.64M |
| 5 |
Takeda Pharmaceutical
TAK
|
+$8.31M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SHPG
Shire pic
SHPG
|
+$28.4M |
| 2 |
Veracyte
VCYT
|
+$14.3M |
| 3 |
ARRY
Array Biopharma Inc
ARRY
|
+$13.2M |
| 4 |
NeoGenomics
NEO
|
+$10.5M |
| 5 |
Omnicell
OMCL
|
+$10.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91% |
| 2 | Communication Services | 4.96% |
| 3 | Miscellaneous | 2.45% |
| 4 | Financials | 0.82% |
| 5 | Energy | 0.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ARRY
1
DELISTED
Array Biopharma Inc
ARRY
| $54.2M | 7.04% |
2,221,721
-632,105
| -22% | -$13.2M |
|
2
Ionis Pharmaceuticals
IONS
$7.85B
| $49.6M | 6.45% |
611,162
+21,152
| +4% | +$1.36M |
|
|
OXFD
3
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $47.3M | 6.14% |
2,743,479
+228,927
| +9% | +$3.62M |
|
|
4
Omnicell
OMCL
$1.49B
| $42.2M | 5.48% |
522,049
-138,606
| -21% | -$10.4M |
|
|
MODN
5
DELISTED
MODEL N, INC.
MODN
| $38.2M | 4.96% |
2,175,594
+449,190
| +26% | +$7.18M |
|
|
6
NeoGenomics
NEO
$2.43B
| $32.8M | 4.27% |
1,604,611
-603,577
| -27% | -$10.5M |
|
7
Harvard Bioscience
HBIO
$36.4M
| $30.5M | 3.96% |
707,024
+6,065
| +0.9% | +$220K |
|
8
Heron Therapeutics
HRTX
$59.6M
| $27.2M | 3.53% |
1,112,966
+287,697
| +35% | +$7.53M |
|
|
SPNE
9
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $27.1M | 3.53% |
1,800,235
+15,164
| +0.8% | +$234K |
|
|
IMMU
10
DELISTED
Immunomedics Inc
IMMU
| $27M | 3.51% |
1,404,713
+44,433
| +3% | +$716K |
|
11
Nektar Therapeutics
NKTR
$2.28B
| $25.6M | 3.33% |
50,894
+2,212
| +5% | +$1.31M |
|
12
AtriCure
ATRC
$2.86B
| $24.5M | 3.18% |
914,307
-51,490
| -5% | -$1.56M |
|
|
13
Halozyme
HALO
$12.1B
| $23.7M | 3.08% |
1,471,498
+533,099
| +57% | +$8.64M |
|
|
XENT
14
DELISTED
Intersect ENT, Inc
XENT
| $23.2M | 3.01% |
720,240
+18,842
| +3% | +$583K |
|
|
MYOK
15
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $22.9M | 2.97% |
+439,635
| New | +$20.3M |
|
|
AERI
16
DELISTED
Aerie Pharmaceuticals
AERI
| $22.5M | 2.93% |
+474,066
| New | +$20.9M |
|
|
17
Veracyte
VCYT
$3.23B
| $19.3M | 2.51% |
772,579
-750,826
| -49% | -$14.3M |
|
18
Tandem Diabetes Care
TNDM
$1.13B
| $17M | 2.21% |
267,954
+4,071
| +2% | +$214K |
|
19
Ligand Pharmaceuticals
LGND
$5.52B
| $16.5M | 2.15% |
210,889
+59,595
| +39% | +$4.52M |
|
20
Xencor
XNCR
$1.77B
| $15.9M | 2.06% |
511,328
+45,558
| +10% | +$1.52M |
|
21
Codexis
CDXS
$153M
| $14.9M | 1.93% |
723,760
-335,599
| -32% | -$6.52M |
|
|
NVTR
22
DELISTED
Nuvectra Corporation Common Stock
NVTR
| $14.7M | 1.91% |
1,338,067
+175,616
| +15% | +$2.37M |
|
|
KDNY
23
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $14.4M | 1.87% |
722,334
+8,543
| +1% | +$149K |
|
|
DVAX
24
DELISTED
Dynavax Technologies
DVAX
| $12.5M | 1.62% |
1,709,541
+1,364,202
| +395% | +$13.3M |
|
25
Viatris
VTRS
$19.1B
| $9.24M | 1.2% |
325,905
+158,718
| +95% | +$4.63M |
|
Similar funds
AAM
NPA
SOS
BCM
BFO
AAG
MCIL
TIM
First Light Asset Management's Q1 2019 Portfolio in Review
As of Q1 2019, First Light Asset Management held 67 positions worth $770M, up 23% from $627M the previous quarter. Its ten largest holdings account for 49% of the portfolio.
First Light Asset Management's Q1 2019 filing shows 8 new, 35 increased, 18 reduced and 4 closed positions. Its largest new stake was Aerie Pharmaceuticals: 474,066 shares worth $22.5M. The largest sale was Shire pic, an estimated $28.4M.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 92% a quarter earlier, followed by Communication Services and Miscellaneous.
- First Light Asset Management's largest Q1 2019 buy was Aerie Pharmaceuticals: 474,066 shares worth $22.5M.
- First Light Asset Management added most to Dynavax Technologies in Q1 2019, an estimated $13.3M increase.
- First Light Asset Management's biggest Q1 2019 reduction was Veracyte, cutting an estimated $14.3M.
- First Light Asset Management fully exited Shire pic in Q1 2019, selling an estimated $28.4M.
- First Light Asset Management's ten largest holdings make up 49% of its $770M portfolio in Q1 2019.
- First Light Asset Management opened 8 new positions and closed 4 in Q1 2019.
- First Light Asset Management's portfolio value rose 23% quarter-over-quarter to $770M.
Based on First Light Asset Management's 13F filing for Q1 2019, filed 15 May 2019.